Innovita Biological Technology Co., Ltd. (SHA:688253)
32.54
+1.68 (5.44%)
At close: May 8, 2025, 2:57 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Respiratory Tract Series - Non-COVID-19 Products | 405.49M |
Log In |
Log In |
Log In |
Log In |
Respiratory Tract Series - Non-COVID-19 Products Growth | - |
Log In |
Log In |
Log In |
Log In |
Respiratory Tract Series - COVID-19 Products | 58.21M |
Log In |
Log In |
Log In |
Log In |
Respiratory Tract Series - COVID-19 Products Growth | - |
Log In |
Log In |
Log In |
Log In |
Other Series | 9.64M |
Log In |
Log In |
Log In |
Log In |
Other Series Growth | -35.97% |
Log In |
Log In |
Log In |
Log In |
Eugenics and Nurturing Series | 4.14M |
Log In |
Log In |
Log In |
Log In |
Eugenics and Nurturing Series Growth | 8.31% |
Log In |
Log In |
Log In |
Log In |
Point-of-care Testing Diagnostic Instrument | 530.97K |
Log In |
Log In |
Log In |
Log In |
Point-of-care Testing Diagnostic Instrument Growth | 200.00% |
Log In |
Log In |
Log In |
Log In |
Respiratory Tract Series | - |
Log In |
Log In |
Log In |
Log In |
In Vitro Diagnostic Testing Equipment | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
China | 464.96M |
Log In |
Log In |
Log In |
Log In |
China Growth | 10.45% |
Log In |
Log In |
Log In |
Log In |
Overseas (including Hong Kong, Macau and Taiwan) | 13.06M |
Log In |
Log In |
Log In |
Log In |
Overseas (including Hong Kong, Macau and Taiwan) Growth | -49.12% |
Log In |
Log In |
Log In |
Log In |